$SGNT (Sagent Pharmaceuticals, Inc.)

$SGNT {{ '2016-06-16T12:22:12+0000' | timeago}} • Announcement

$SGNT said total market sales for the five ANDAs are $340MM on a trailing twelve month basis. The portfolio is expected to generate $40-50MM in revenue on an annualized basis. $SGNT will finance the transaction through its existing $80MM revolving credit facility, which currently has no borrowings outstanding.

$VRTX {{ '2018-01-10T15:15:09+0000' | timeago}} • Announcement

$VRTX said the European Commission has granted extension of the Marketing Authorization for ORKAMBI, intended for the treatment of cystic fibrosis (CF) in people with two copies of the F508del mutation, to include children ages 6 through 11. Existing reimbursement agreements in countries such as Ireland will enable rapid access to ORKAMBI.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$MLNT {{ '2018-01-08T17:08:01+0000' | timeago}} • Announcement

$MLNT completed the acquisition of $MDCO’s infectious disease business. $MLNT also announced that $MDCO’s Mike McGuire has joined the new organization as SVP, Commercial, replacing Chief Commercial Officer, John Temperato, who left $MLNT to pursue other opportunities.

$MDCO {{ '2018-01-08T13:17:52+0000' | timeago}} • Announcement

Pharma firm $MDCO closed the sale of its infectious disease business to $MLNT for $215MM of guaranteed cash and 3.3 MM common shares of Melinta. The sale consideration also includes royalty payments of 5-25% on certain drug sales and the assumption by Melinta of all royalty, milestone and other payment obligations relating to those products.

$ACOR {{ '2018-01-08T12:56:05+0000' | timeago}} • Announcement

Bio-pharmaceuticals company $ACOR has reported net sales of $542MM for fiscal 2017. For fiscal 2018, the company expects net sales to be in the range of $330MM to $350MM. R&D and SG&A operating expenses, on an adjusted basis, is forecasted in the $270-$290MM range.

$PFE {{ '2018-01-04T13:11:11+0000' | timeago}} • Announcement

Arvinas LLC collaborates with $PFE for the discovery and development of drug candidates using Arvinas' PROTAC Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Arvinas may receive up to $830MM in upfront and potential development and commercialization milestone payments.

$ACET {{ '2018-01-02T20:11:33+0000' | timeago}} • Announcement

$ACET's finished dosage form generics subsidiary Rising Pharmaceuticals launched the first generic for Efavirenz Capsules. This is an FDA-approved generic version of the reference listed drug, Sustiva from $BMY, which in combination with other drugs is indicated for the treatment of HIV-1 infection in adults and pediatric patients.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

$MRK {{ '2017-12-22T16:34:34+0000' | timeago}} • Announcement

$MRK and $PFE announced that the FDA approved STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

$PFE {{ '2017-12-21T21:14:41+0000' | timeago}} • Announcement

$PFE announced that the US FDA has granted Breakthrough Therapy Designation for avelumab in combination with INLYTA for treatment-naive patients with advanced renal cell carcinoma (RCC). This is the second Breakthrough Therapy Designation granted to avelumab.

$PFE {{ '2017-12-20T12:23:04+0000' | timeago}} • Announcement

The US FDA has approved $PFE's supplemental New Drug Application to expand the indication for BOSULIF  to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph CML).

$PFE {{ '2017-12-18T19:31:58+0000' | timeago}} • Announcement

The BoD of $PFE has increased the quarterly dividend by 6% to $0.34 per share. The first quarter 2018 cash dividend will be payable on March 1, 2018, to shareholders of record on Feb. 2, 2018. The board also authorized a new $10Bil share repurchase program, in addition to the $6.4Bil remaining under the current authorization.

$REGN {{ '2017-12-18T12:38:12+0000' | timeago}} • Announcement

$REGN and ISA Pharmaceuticals announced a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. $REGN and ISA will jointly conduct trials of treatment in cervical cancer and head-and-neck cancer.

$VRTX {{ '2017-12-12T14:48:16+0000' | timeago}} • Announcement

$VRTX and $CRSP will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of a collaboration aimed at the development of new gene editing treatments that use the CRISPR/Cas9 technology. For CTX001, both companies will equally share all research and development costs and profits worldwide.

$ZTS {{ '2017-12-12T13:32:16+0000' | timeago}} • Announcement

$ZTS BoD declared 1Q18 dividend of $0.126 per share of the company’s common stock, an increase of 20% from the quarterly dividend rate paid in 2017. The dividend is to be paid on Thursday, March 1, 2018, to holders of record on Friday, January 19, 2018.

$LLY {{ '2017-12-11T17:36:13+0000' | timeago}} • Announcement

FDA accepts to review $LLY's Galcanezumab, an injectionable drug for the treatment of migraine. Rivals $NVS and $AMGN already filed their migraine drug with FDA in July 2017, while $TEVA is also expected to join the race. Lilly's pain portfolio also includes Tanezumab, developed in partnership with $PFE, for the treatment of osteoarthritis.

$JCI {{ '2017-12-11T16:43:09+0000' | timeago}} • Announcement

$JCI's BoD appointed John Young to serve as a director. Young is currently group president of $PFE Essential Health. Effective Jan. 1, 2018, he will become group president of Pfizer Innovative Health, which comprises six business groups focused on improving health through innovative products covering every stage of life.

$ACET {{ '2017-12-07T22:37:45+0000' | timeago}} • Announcement

$ACET has declared a regular quarterly dividend of $0.065 per common share, payable on December 28, 2017 to shareholders of record as of December 18, 2017.

$ACOR {{ '2017-12-07T14:24:01+0000' | timeago}} • Announcement

$ACOR announced the resubmission of its New Drug Application (NDA) for INBRIJA to the US FDA. INBRIJA is an investigational treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. FDA is expected to inform $ACOR within 74 days if the submission has been deemed complete and permits a full review.

$PFE {{ '2017-12-01T11:52:44+0000' | timeago}} • Announcement

$PFE enters into agreement with Basilea Pharmaceutica Ltd to develop and commercialize CRESEMBA in China and Asia Pacific region. CRESEMBA is a novel antifungal medicine for the treatment of adult patients with diagnosed invasive aspergillosis and mucormycosis.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
TARO (Taro Pharmaceutical Industries Ltd.)
Wednesday, November 8 2017 - 1:00pm
CBM (Cambrex Corporation.)
Tuesday, November 7 2017 - 1:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
ACET (Aceto Corp.)
Friday, November 3 2017 - 1:00pm
ZTS (Zoetis Inc.)
Thursday, November 2 2017 - 12:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, November 2 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
ACOR (Acorda Therapeutics, Inc.)
Tuesday, October 31 2017 - 12:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, October 26 2017 - 8:30pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, October 25 2017 - 8:30pm
MDCO (The Medicines Company)
Wednesday, October 25 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
ACET (Aceto Corp.)
Friday, August 25 2017 - 1:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm

AlphaGraphics you may like